Status:
COMPLETED
Hepcidine and Iron Deficiency in Critically Ill Patients
Lead Sponsor:
University Hospital, Montpellier
Conditions:
Anemia
Critical Illness
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Anaemia is very frequent among critically ill patients, concerning more than 60 % of them at admission and more than 80% at intensive care unit discharge. Iron deficiency is also frequent at admission...
Eligibility Criteria
Inclusion
- Hospitalized man/woman in reanimation unit for at least 5 days.
- Age ≥ 18 years old.
- Patient having an anaemia such as defined by the WHO (World Health Organization) (for man: Hemoglobin \< 13 g/dl, for woman: Hemoglobin \< 12 g/dl).
- Signed inform consent by the patient or a close person.
- Subject affiliated to a national health insurance
Exclusion
- Known iron metabolism pathology (such as primitive or secondary hemochromatosis, …).
- Chronic anaemia (Hemoglobin ≤ 10 g/dl for more than 3 months).
- Current chemotherapy.
- Patient having an organ transplant
- Expected survival \< 28 days post Intensive Care Unit discharge.
- Pregnancy
- Patient deprived of freedom, by judicial or administrative order.
- Major protected by the law.
- Contra-indication to the injectable iron treatment (allergy to ferric carboxymaltose, infection derivates (bacteriamy \< 48 hours) untreated).
- Non speaking French patient, or patient unable to answer a questionnaire because of any neurologic disorder (stroke, brain trauma….).
Key Trial Info
Start Date :
August 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2017
Estimated Enrollment :
408 Patients enrolled
Trial Details
Trial ID
NCT02276690
Start Date
August 1 2014
End Date
September 1 2017
Last Update
October 6 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Anesthesiology & Critical Care, Angers University Hospital, 4 rue larrey
Angers, France, 49000